Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)
Open Posted
- Opportunity number
- RFA-AI-28-024
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Category
-
- Health
- Eligible applicants
-
- Non-501(c)(3) Nonprofits
- Tribal Governments (Federally Recognized)
- Independent School Districts
- Small Businesses
- County Governments
- Special District Governments
- Other
- Public or Indian Housing Auth.
- 501(c)(3) Nonprofits
- For Profit Organizations
- Higher Education Inst. (Private)
- Higher Education Inst. (Public)
- City/Township Governments
- Tribal Organizations (Not Federally Recognized)
- State Governments
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institute of Allergy and Infectious Diseases (NIAID) seeks applicants for basic research, discovery, and preclinical development of highly efficacious vaccines against malaria and potentially other mosquito-borne diseases, with applications due February 11, 2027. Clinical trials are not allowed under this R61/R33 mechanism.
Eligible applicants include public and private higher education institutions, state and local governments, federally recognized and other Indian tribes, 501(c)(3) and non-501(c)(3) nonprofits, small businesses, for-profit organizations, independent school districts, special districts, public and Indian housing authorities, eligible federal agencies, U.S. territories or possessions, faith-based or community-based organizations, regional organizations, and non-domestic entities. Non-domestic components of U.S. organizations and foreign components are permitted; however, applications involving foreign subawards or subcontracts will be deemed noncompliant unless submitted to a NOFO specifically designated for funded international collaborations. Unfunded international collaborations, foreign consultants, and procurement of unique equipment or supplies from foreign vendors remain permissible.
The program prioritizes novel approaches to vaccine design leveraging recent technological innovations, particularly structure-based immunogen design, improved formulations, and combination vaccines. Applications should address technical, immunological, or logistical barriers to vaccine efficacy and articulate how proposed research could serve as a model for or achieve effectiveness against other mosquito-borne diseases.
Review criteria assess scientific merit and significance, technical adequacy of experimental design, investigator competency, facility adequacy, budget necessity relative to proposed work, and relevance to program objectives. All applications undergo peer review by an appropriate initial review group and the National Advisory Allergy and Infectious Diseases Council.
Funding is provided under CFDA 93.855 (Allergy and Infectious Diseases Research) using grant authorities derived from Sections 301 and 405 of the Public Health Service Act and Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
Synopsis
The purpose of this notice of funding opportunity (NOFO) is to support research and/or preclinical development of highly efficacious vaccines against malaria - one of the deadliest mosquito-borne diseases - by capitalizing on recent technological innovations, particularly in structure-based immunogen design, improved formulations, and combination vaccines. The goal is to achieve long-lasting, highly effective protection that can save lives, strengthen public health security in the United States, and serve as a model for, or are potentially effective against, other mosquito-borne diseases.
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibilityForeign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.
Files
| File | Type | Posted |
|---|---|---|
| PKG00294369.pdf | ||
| RFA-AI-28-024-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity